The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Bronchopulmonary Dysplasia-Global Market Insights and Sales Trends 2024
Synopsis
Bronchopulmonary dysplasia, a type of chronic lung disorder, affects newborns, mostly premature and infants. Lungs and bronchi are damaged at the neonatal phase which causes destruction of tiny air sacs known as alveoli. Babies are not born with the disease. The condition is developed when premature infants need aid to breathe for a longer period, leading to inflammation and lung scarring. Infants with this disease exhibit signs and symptoms such as rapid breathing and faster heart rate. The disease is life threatening however, the severity of the disease varies.
The global Bronchopulmonary Dysplasia market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Bronchopulmonary Dysplasia in various end use industries. The expanding demands from the Clinic, Hospital and Others,, are propelling Bronchopulmonary Dysplasia market. Surfactant Replacement Therapy, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Oxygen Therapy segment is estimated at % CAGR for the next seven-year period.
The global bronchopulmonary dysplasia treatment market is expected to expand at a steady CAGR during the forecast period. According to the Journal of Clinical Medicine, 10,000 to 15,000 new cases of the disorder are reported each year in the U.S. alone. High prevalence of the diseases is expected to drive the global bronchopulmonary dysplasia treatment market during the forecast period. According to the WHO, 15 million babies are born preterm which is another factor contributing to the growth of the market. Furthermore, government initiatives, favorable reimbursement policies, launch of novel drugs, strong pipeline, rising premature birth cases, and increase in health care expenditure are factors likely to propel the global bronchopulmonary dysplasia treatment market during the forecast period. Long-term side effects of drugs, high cost of treatment, and lack of awareness in developing countries are factors anticipated to restrain the global market during the forecast period.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Bronchopulmonary Dysplasia, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Bronchopulmonary Dysplasia market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Bronchopulmonary Dysplasia market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Bronchopulmonary Dysplasia sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Bronchopulmonary Dysplasia covered in this report include Chiesi Farmaceutici, Discovery Laboratories, Takeda Pharmaceutical Company, MediPost, Clarassance and Syntrix Biosystems, etc.
The global Bronchopulmonary Dysplasia market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Chiesi Farmaceutici
Discovery Laboratories
Takeda Pharmaceutical Company
MediPost
Clarassance
Syntrix Biosystems
Global Bronchopulmonary Dysplasia market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Bronchopulmonary Dysplasia market, Segment by Type:
Surfactant Replacement Therapy
Oxygen Therapy
Supportive Therapy
Others
Global Bronchopulmonary Dysplasia market, by Application
Clinic
Hospital
Others
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Bronchopulmonary Dysplasia companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Bronchopulmonary dysplasia, a type of chronic lung disorder, affects newborns, mostly premature and infants. Lungs and bronchi are damaged at the neonatal phase which causes destruction of tiny air sacs known as alveoli. Babies are not born with the disease. The condition is developed when premature infants need aid to breathe for a longer period, leading to inflammation and lung scarring. Infants with this disease exhibit signs and symptoms such as rapid breathing and faster heart rate. The disease is life threatening however, the severity of the disease varies.
The global Bronchopulmonary Dysplasia market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Bronchopulmonary Dysplasia in various end use industries. The expanding demands from the Clinic, Hospital and Others,, are propelling Bronchopulmonary Dysplasia market. Surfactant Replacement Therapy, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Oxygen Therapy segment is estimated at % CAGR for the next seven-year period.
The global bronchopulmonary dysplasia treatment market is expected to expand at a steady CAGR during the forecast period. According to the Journal of Clinical Medicine, 10,000 to 15,000 new cases of the disorder are reported each year in the U.S. alone. High prevalence of the diseases is expected to drive the global bronchopulmonary dysplasia treatment market during the forecast period. According to the WHO, 15 million babies are born preterm which is another factor contributing to the growth of the market. Furthermore, government initiatives, favorable reimbursement policies, launch of novel drugs, strong pipeline, rising premature birth cases, and increase in health care expenditure are factors likely to propel the global bronchopulmonary dysplasia treatment market during the forecast period. Long-term side effects of drugs, high cost of treatment, and lack of awareness in developing countries are factors anticipated to restrain the global market during the forecast period.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Bronchopulmonary Dysplasia, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Bronchopulmonary Dysplasia market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Bronchopulmonary Dysplasia market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Bronchopulmonary Dysplasia sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Bronchopulmonary Dysplasia covered in this report include Chiesi Farmaceutici, Discovery Laboratories, Takeda Pharmaceutical Company, MediPost, Clarassance and Syntrix Biosystems, etc.
The global Bronchopulmonary Dysplasia market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Chiesi Farmaceutici
Discovery Laboratories
Takeda Pharmaceutical Company
MediPost
Clarassance
Syntrix Biosystems
Global Bronchopulmonary Dysplasia market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Bronchopulmonary Dysplasia market, Segment by Type:
Surfactant Replacement Therapy
Oxygen Therapy
Supportive Therapy
Others
Global Bronchopulmonary Dysplasia market, by Application
Clinic
Hospital
Others
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Bronchopulmonary Dysplasia companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Index1 Market Overview of Bronchopulmonary Dysplasia
1.1 Bronchopulmonary Dysplasia Market Overview
1.1.1 Bronchopulmonary Dysplasia Product Scope
1.1.2 Bronchopulmonary Dysplasia Market Status and Outlook
1.2 Global Bronchopulmonary Dysplasia Market Size Overview by Region 2018 VS 2022 VS 2029
1.3 Global Bronchopulmonary Dysplasia Market Size by Region (2018-2029)
1.4 Global Bronchopulmonary Dysplasia Historic Market Size by Region (2018-2023)
1.5 Global Bronchopulmonary Dysplasia Market Size Forecast by Region (2024-2029)
1.6 Key Regions, Bronchopulmonary Dysplasia Market Size (2018-2029)
1.6.1 North America Bronchopulmonary Dysplasia Market Size (2018-2029)
1.6.2 Europe Bronchopulmonary Dysplasia Market Size (2018-2029)
1.6.3 Asia-Pacific Bronchopulmonary Dysplasia Market Size (2018-2029)
1.6.4 Latin America Bronchopulmonary Dysplasia Market Size (2018-2029)
1.6.5 Middle East & Africa Bronchopulmonary Dysplasia Market Size (2018-2029)
2 Bronchopulmonary Dysplasia Market by Type
2.1 Introduction
2.1.1 Surfactant Replacement Therapy
2.1.2 Oxygen Therapy
2.1.3 Supportive Therapy
2.1.4 Others
2.2 Global Bronchopulmonary Dysplasia Market Size by Type: 2018 VS 2022 VS 2029
2.2.1 Global Bronchopulmonary Dysplasia Historic Market Size by Type (2018-2023)
2.2.2 Global Bronchopulmonary Dysplasia Forecasted Market Size by Type (2024-2029)
2.3 Key Regions Market Size by Type
2.3.1 North America Bronchopulmonary Dysplasia Revenue Breakdown by Type (2018-2029)
2.3.2 Europe Bronchopulmonary Dysplasia Revenue Breakdown by Type (2018-2029)
2.3.3 Asia-Pacific Bronchopulmonary Dysplasia Revenue Breakdown by Type (2018-2029)
2.3.4 Latin America Bronchopulmonary Dysplasia Revenue Breakdown by Type (2018-2029)
2.3.5 Middle East and Africa Bronchopulmonary Dysplasia Revenue Breakdown by Type (2018-2029)
3 Bronchopulmonary Dysplasia Market Overview by Application
3.1 Introduction
3.1.1 Clinic
3.1.2 Hospital
3.1.3 Others
3.2 Global Bronchopulmonary Dysplasia Market Size by Application: 2018 VS 2022 VS 2029
3.2.1 Global Bronchopulmonary Dysplasia Historic Market Size by Application (2018-2023)
3.2.2 Global Bronchopulmonary Dysplasia Forecasted Market Size by Application (2024-2029)
3.3 Key Regions Market Size by Application
3.3.1 North America Bronchopulmonary Dysplasia Revenue Breakdown by Application (2018-2029)
3.3.2 Europe Bronchopulmonary Dysplasia Revenue Breakdown by Application (2018-2029)
3.3.3 Asia-Pacific Bronchopulmonary Dysplasia Revenue Breakdown by Application (2018-2029)
3.3.4 Latin America Bronchopulmonary Dysplasia Revenue Breakdown by Application (2018-2029)
3.3.5 Middle East and Africa Bronchopulmonary Dysplasia Revenue Breakdown by Application (2018-2029)
4 Bronchopulmonary Dysplasia Competition Analysis by Players
4.1 Global Bronchopulmonary Dysplasia Market Size by Players (2018-2023)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Bronchopulmonary Dysplasia as of 2022)
4.3 Date of Key Players Enter into Bronchopulmonary Dysplasia Market
4.4 Global Top Players Bronchopulmonary Dysplasia Headquarters and Area Served
4.5 Key Players Bronchopulmonary Dysplasia Product Solution and Service
4.6 Competitive Status
4.6.1 Bronchopulmonary Dysplasia Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 Chiesi Farmaceutici
5.1.1 Chiesi Farmaceutici Profile
5.1.2 Chiesi Farmaceutici Main Business
5.1.3 Chiesi Farmaceutici Bronchopulmonary Dysplasia Products, Services and Solutions
5.1.4 Chiesi Farmaceutici Bronchopulmonary Dysplasia Revenue (US$ Million) & (2018-2023)
5.1.5 Chiesi Farmaceutici Recent Developments
5.2 Discovery Laboratories
5.2.1 Discovery Laboratories Profile
5.2.2 Discovery Laboratories Main Business
5.2.3 Discovery Laboratories Bronchopulmonary Dysplasia Products, Services and Solutions
5.2.4 Discovery Laboratories Bronchopulmonary Dysplasia Revenue (US$ Million) & (2018-2023)
5.2.5 Discovery Laboratories Recent Developments
5.3 Takeda Pharmaceutical Company
5.3.1 Takeda Pharmaceutical Company Profile
5.3.2 Takeda Pharmaceutical Company Main Business
5.3.3 Takeda Pharmaceutical Company Bronchopulmonary Dysplasia Products, Services and Solutions
5.3.4 Takeda Pharmaceutical Company Bronchopulmonary Dysplasia Revenue (US$ Million) & (2018-2023)
5.3.5 MediPost Recent Developments
5.4 MediPost
5.4.1 MediPost Profile
5.4.2 MediPost Main Business
5.4.3 MediPost Bronchopulmonary Dysplasia Products, Services and Solutions
5.4.4 MediPost Bronchopulmonary Dysplasia Revenue (US$ Million) & (2018-2023)
5.4.5 MediPost Recent Developments
5.5 Clarassance
5.5.1 Clarassance Profile
5.5.2 Clarassance Main Business
5.5.3 Clarassance Bronchopulmonary Dysplasia Products, Services and Solutions
5.5.4 Clarassance Bronchopulmonary Dysplasia Revenue (US$ Million) & (2018-2023)
5.5.5 Clarassance Recent Developments
5.6 Syntrix Biosystems
5.6.1 Syntrix Biosystems Profile
5.6.2 Syntrix Biosystems Main Business
5.6.3 Syntrix Biosystems Bronchopulmonary Dysplasia Products, Services and Solutions
5.6.4 Syntrix Biosystems Bronchopulmonary Dysplasia Revenue (US$ Million) & (2018-2023)
5.6.5 Syntrix Biosystems Recent Developments
6 North America
6.1 North America Bronchopulmonary Dysplasia Market Size by Country (2018-2029)
6.2 U.S.
6.3 Canada
7 Europe
7.1 Europe Bronchopulmonary Dysplasia Market Size by Country (2018-2029)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Bronchopulmonary Dysplasia Market Size by Region (2018-2029)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Bronchopulmonary Dysplasia Market Size by Country (2018-2029)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Bronchopulmonary Dysplasia Market Size by Country (2018-2029)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Bronchopulmonary Dysplasia Market Dynamics
11.1 Bronchopulmonary Dysplasia Industry Trends
11.2 Bronchopulmonary Dysplasia Market Drivers
11.3 Bronchopulmonary Dysplasia Market Challenges
11.4 Bronchopulmonary Dysplasia Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
